Results 51 to 60 of about 419,175 (164)

Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. [PDF]

, 2014
The age at diagnosis of pulmonary arterial hypertension (PAH) and the prevalence of cardiovascular (CV) risk factors are increasing. We sought to determine whether the response to drug therapy was influenced by CV risk factors in PAH patients. We studied
Charalampopoulos, A, Connolly, SB, Davies, RJ, Gibbs, JS, Gin-Sing, W, Grapsa, J, Howard, LS, Nihoyannopoulos, P, Tzoulaki, I, Wilkins, MR   +9 more
core   +1 more source

Genetics and genomics of pulmonary arterial hypertension

European Respiratory Journal, 2019
Since 2000 there have been major advances in our understanding of the genetic and genomics of pulmonary arterial hypertension (PAH), although there remains much to discover. Based on existing knowledge, around 25–30% of patients diagnosed with idiopathic
N. Morrell, M. Aldred, W. Chung, C. G. Elliott, William C Nichols, F. Soubrier, R. Trembath, James E. Loyd   +7 more
semanticscholar   +1 more source

Three-dimensional echocardiography and 2D-3D speckle tracking imaging in chronic pulmonary hypertension. diagnostic accuracy in detecting hemodynamic signs of RV failure [PDF]

, 2015
Background and objective. Our aim was to compare three-dimensional (3D) and 2D and 3D speckle tracking (2D-STE, 3D-STE) echocardiographic parameters with conventional right ventricular (RV) indexes in patients with chronic pulmonary hypertension (PH ...
Alessia, Azzano, Capotosto, Lidia, Gaudio, Carlo, Mangieri, Enrico, Nino, Cocco, Rasul, Ashurov, Rosato, Edoardo, Salsano, Felice, Simona, D’Orazio, Terzano, Claudio, Truscelli, Giovanni, Vitarelli, Antonino   +11 more
core   +1 more source

Glucocorticoids for treating paediatric pulmonary hypertension: A novel use for a common medication [PDF]

, 2017
Laboratory investigations have shown the role of inflammation in the pathogenesis of pulmonary hypertension and improvement after anti-inflammatory drugs.
Aggarwal, Manish, Grady, Ronald M
core   +2 more sources

Blockade of JAK2 protects mice against hypoxia‐induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation

Cell Proliferation, 2020
Hypoxia is an important risk factor for pulmonary arterial remodelling in pulmonary arterial hypertension (PAH), and the Janus kinase 2 (JAK2) is believed to be involved in this process.
Lei Zhang, Yi Wang, Guorao Wu, Lizong Rao, Yanqiu Wei, H. Yue, Ting Yuan, Ping Yang, Fei Xiong, Shu Zhang, Qing Zhou, Zhishui Chen, Jinxiu Li, B. Mo, Huilan Zhang, W. Xiong, Cong-Yi Wang   +16 more
semanticscholar   +1 more source

Micro-RNA-1 is decreased by hypoxia and contributes to the development of pulmonary vascular remodeling via regulation of sphingosine kinase 1 [PDF]

, 2018
Sphingosine kinase 1 (SphK1) upregulation is associated with pathologic pulmonary vascular remodeling in pulmonary arterial hypertension (PAH), but the mechanisms controlling its expression are undefined.
Chen, Jiwang, Comhair, Suzy, Machado, Roberto F., Natarajan, Viswanathan, Singla, Sunit, Sysol, Justin R., Zhao, Shuangping   +6 more
core   +1 more source

The trajectory to diagnosis with pulmonary arterial hypertension: a qualitative study [PDF]

, 2012
Objectives To investigate the patient's experience of the trajectory to receiving a diagnosis of pulmonary arterial hypertension (PAH) and inform the provision of care for this patient group.
Armstrong, I, Bundock, S, Harries, C, Rochnia, NK, Yorke, J   +4 more
core   +2 more sources

Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic

Pulmonary Circulation, 2020
The COVID-19 pandemic presents many unique challenges when caring for patients with pulmonary hypertension. The COVID-19 pandemic has altered routine standard of care practice and the acute management particularly for those patients with pulmonary ...
J. Ryan, L. Melendres‐Groves, R. Zamanian, R. Oudiz, M. Chakinala, E. Rosenzweig, M. Gomberg-Maitland   +6 more
semanticscholar   +1 more source

Identification of rare sequence variation underlying heritable pulmonary arterial hypertension

Nature Communications, 2018
Pulmonary arterial hypertension (PAH) is a rare disorder with a poor prognosis. Deleterious variation within components of the transforming growth factor-β pathway, particularly the bone morphogenetic protein type 2 receptor (BMPR2), underlies most ...
S. Gräf, M. Haimel, M. Bleda, C. Hadinnapola, L. Southgate, L. Southgate, Wei Li, J. Hodgson, Bin Liu, R. Salmon, M. Southwood, R. Machado, Jennifer M. Martin, C. Treacy, C. Treacy, Katherine Yates, L. Daugherty, O. Shamardina, Deborah Whitehorn, Simon Holden, M. Aldred, H. Bogaard, Colin Church, G. Coghlan, R. Condliffe, P. Corris, C. Danesino, M. Eyries, Henning Gall, Stefano Ghio, H. Ghofrani, H. Ghofrani, J. S. R. Gibbs, B. Girerd, A. Houweling, Luke Howard, Marc Humbert, D. Kiely, Gabor Kovacs, R. Ross, S. Moledina, D. Montani, M. Newnham, Andrea Olschewski, H. Olschewski, A. Peacock, Joanna Pepke-Zaba, Inga Prokopenko, Christopher J. Rhodes, L. Scelsi, Werner Seeger, F. Soubrier, D. Stein, J. Suntharalingam, E. Swietlik, M. Toshner, D. A. Heel, A. Noordegraaf, Q. Waisfisz, J. Wharton, S. J. Wort, W. Ouwehand, Nicole Soranzo, Nicole Soranzo, A. Lawrie, P. Upton, Martin R. Wilkins, R. Trembath, N. Morrell   +68 more
semanticscholar   +1 more source

Relationship of daily arterial blood pressure monitoring readings and arterial stiffness profile in male patients with chronic obstructive pulmonary disease combined with arterial hypertension [PDF]

, 2013
The aim of the study was to determine correlation between arterial blood pressure daily rhythm and daily profile of arterial stiffness in male patients with chronic obstructive pulmonary disease (COPD) and arterial hypertension.
Borodkin A.M., Dolishnyaya G.R., Karoli N.A., Rebrov A.P.   +3 more
core